JP7569216B2 - ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法 - Google Patents

２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法 Download PDF

Info

Publication number
JP7569216B2
JP7569216B2 JP2020537156A JP2020537156A JP7569216B2 JP 7569216 B2 JP7569216 B2 JP 7569216B2 JP 2020537156 A JP2020537156 A JP 2020537156A JP 2020537156 A JP2020537156 A JP 2020537156A JP 7569216 B2 JP7569216 B2 JP 7569216B2
Authority
JP
Japan
Prior art keywords
raav
vector
aav
cyp21
adrenal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020537156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511020A (ja
JP2021511020A5 (https=
Inventor
ピエール ブニェール，
グアンピン ガオ，
Original Assignee
アドリーナス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドリーナス セラピューティクス， インコーポレイテッド filed Critical アドリーナス セラピューティクス， インコーポレイテッド
Publication of JP2021511020A publication Critical patent/JP2021511020A/ja
Publication of JP2021511020A5 publication Critical patent/JP2021511020A5/ja
Priority to JP2023062403A priority Critical patent/JP2023076698A/ja
Application granted granted Critical
Publication of JP7569216B2 publication Critical patent/JP7569216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2020537156A 2018-01-17 2019-01-17 ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法 Active JP7569216B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023062403A JP2023076698A (ja) 2018-01-17 2023-04-06 ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862618307P 2018-01-17 2018-01-17
US62/618,307 2018-01-17
US201862640311P 2018-03-08 2018-03-08
US62/640,311 2018-03-08
PCT/US2019/013991 WO2019143803A1 (en) 2018-01-17 2019-01-17 Adeno-associated virus gene therapy for 21-hydroxylase deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023062403A Division JP2023076698A (ja) 2018-01-17 2023-04-06 ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法

Publications (3)

Publication Number Publication Date
JP2021511020A JP2021511020A (ja) 2021-05-06
JP2021511020A5 JP2021511020A5 (https=) 2022-01-26
JP7569216B2 true JP7569216B2 (ja) 2024-10-17

Family

ID=65494499

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020537156A Active JP7569216B2 (ja) 2018-01-17 2019-01-17 ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法
JP2023062403A Pending JP2023076698A (ja) 2018-01-17 2023-04-06 ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023062403A Pending JP2023076698A (ja) 2018-01-17 2023-04-06 ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法

Country Status (8)

Country Link
US (2) US12195767B2 (https=)
EP (1) EP3740244B1 (https=)
JP (2) JP7569216B2 (https=)
KR (1) KR102892243B1 (https=)
CN (1) CN111601620A (https=)
BR (1) BR112020014404A2 (https=)
CA (1) CA3088323A1 (https=)
WO (1) WO2019143803A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022198038A1 (en) 2021-03-19 2022-09-22 Adrenas Therapeutics, Inc. Gene therapies for 21-hydroxylase deficiency
AU2022366947A1 (en) 2021-10-12 2024-05-02 Bridgebio Gene Therapy Llc Methods and compositions for treating leukodystrophies
CN115976004B (zh) * 2022-12-27 2024-07-09 天津科技大学 一种黄体酮17α-羟化酶突变体及其应用
AU2024317892A1 (en) * 2023-07-29 2025-08-28 Limited Liability Company «Genetic Technologies» (Llc «Genetic Technologies») Adeno-associated virus-based expression vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516092A (ja) 1998-05-28 2002-06-04 アメリカ合衆国 Ａａｖ５ベクターおよびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
DK2573170T3 (en) 2001-12-17 2018-04-09 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US8865881B2 (en) * 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
IL297919A (en) 2013-07-22 2023-01-01 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
WO2015041718A1 (en) 2013-09-20 2015-03-26 The General Hospital Corporation Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases
EP3015550A1 (en) 2014-10-30 2016-05-04 Sanofi 21-Hydroxylation of steroids
EP3054006A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
HUE069664T2 (hu) * 2015-07-10 2025-04-28 Univ Guelph Madár-adenovírus 9 (FADV-9) vektorrendszer és kapcsolódó módszerek
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2022198038A1 (en) 2021-03-19 2022-09-22 Adrenas Therapeutics, Inc. Gene therapies for 21-hydroxylase deficiency

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516092A (ja) 1998-05-28 2002-06-04 アメリカ合衆国 Ａａｖ５ベクターおよびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Endocr. J.，2016年，Vol. 63, Issue 10，pp.897-904
Gene Ther.，2017年，Vol. 24，pp.275-281

Also Published As

Publication number Publication date
EP3740244B1 (en) 2025-05-21
JP2021511020A (ja) 2021-05-06
EP3740244A1 (en) 2020-11-25
BR112020014404A2 (pt) 2020-12-29
WO2019143803A1 (en) 2019-07-25
CN111601620A (zh) 2020-08-28
JP2023076698A (ja) 2023-06-01
US20250304925A1 (en) 2025-10-02
KR102892243B1 (ko) 2025-11-27
KR20200110376A (ko) 2020-09-23
CA3088323A1 (en) 2019-07-25
US20210277365A1 (en) 2021-09-09
US12195767B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
US11896652B2 (en) Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues
US20250304925A1 (en) Adeno-associated virus gene therapy for 21-hydroxylase deficiency
JP2025128087A (ja) 神経セロイドリポフスチン症の遺伝子治療
WO2018209205A9 (en) Gene therapy for neuronal ceroid lipofuscinoses
TW202144575A (zh) 使用ａａｖ及治療調配物之苯酮尿症治療
CA3088079A1 (en) Compositions and methods for treating retinal disorders
KR20230159837A (ko) 21-하이드록실라제 결핍에 대한 유전자 요법
US20230136699A1 (en) Gene therapy for maple syrup urine disease
EP4615492A1 (en) Polynucleotide and vector
WO2025060451A1 (zh) 经修饰的腺相关病毒载体及其在治疗神经疾病中的用途
BR112017027956B1 (pt) Vetores de vírus adenoassociado recombinante, uso e método de produção dos mesmos, e composição farmacêutica
HK1252351B (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241004

R150 Certificate of patent or registration of utility model

Ref document number: 7569216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150